Switch theme
Sign up to access all valuation multiples
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
3
Last FY Revenue $0.1M
Last FY EBITDA -$1.0M
$8.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pila Pharma achieved revenue of $0.1M and an EBITDA of -$1.0M.
Pila Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pila Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$1.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1311% | XXX | XXX | XXX |
| EBIT | XXX | -$0.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1046% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.2M | XXX | XXX | XXX |
| Net Margin | XXX | -1451% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pila Pharma's stock price is SEK 3 (or $0).
Pila Pharma has current market cap of SEK 79.9M (or $8.2M), and EV of SEK 77.3M (or $8.0M).
See Pila Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.0M | $8.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pila Pharma has market cap of $8.2M and EV of $8.0M.
Pila Pharma's trades at 99.8x EV/Revenue multiple, and -7.6x EV/EBITDA.
Equity research analysts estimate Pila Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pila Pharma's P/E ratio is not available.
See valuation multiples for Pila Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.2M | XXX | $8.2M | XXX | XXX | XXX |
| EV (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 99.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -7.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPila Pharma's revenue per employee in the last FY averaged $27K, while opex per employee averaged $0.3M for the same period.
Pila Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pila Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pila Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1311% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1146% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pila Pharma acquired XXX companies to date.
Last acquisition by Pila Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Pila Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Pila Pharma headquartered? | Pila Pharma is headquartered in Sweden. |
| How many employees does Pila Pharma have? | As of today, Pila Pharma has 3 employees. |
| Is Pila Pharma publicy listed? | Yes, Pila Pharma is a public company listed on STO. |
| What is the stock symbol of Pila Pharma? | Pila Pharma trades under PILA ticker. |
| When did Pila Pharma go public? | Pila Pharma went public in 2021. |
| Who are competitors of Pila Pharma? | Similar companies to Pila Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pila Pharma? | Pila Pharma's current market cap is $8.2M |
| Is Pila Pharma profitable? | Yes, Pila Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
